文献速递心力衰竭与心肌病血脂与心血管预防

胰岛素抵抗非糖尿病患者缺血性卒中或TIA后吡格列酮与心力衰竭风险:IRIS试验二次分析

Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone.
PubMed 文献 · Circulation · 2018-01-01

IRIS试验二次分析纳入3851例无糖尿病但存在胰岛素抵抗的缺血性卒中或TIA患者,随机接受吡格列酮或安慰剂。5年心衰风险两组无差异(4.1% vs 4.2%),心衰住院风险亦无显著增加(2.9% vs 2.3%,P=0.36);吡格列酮降低卒中、心梗或心衰住院复合终点(HR 0.78,P=0.007)。

要点

  • 吡格列酮未增加胰岛素抵抗卒中/TIA患者5年心衰风险,基线心衰风险不影响该效应。
  • 吡格列酮降低卒中、心梗或心衰住院复合终点(HR 0.78,P=0.007)。
  • 水肿、呼吸困难、体重增加不预测心衰住院,但导致更多剂量下调。

核心结论

  • 在监测和剂量调整下,吡格列酮未增加胰岛素抵抗合并脑血管病患者的HF风险,并带来净心血管获益。
  • 吡格列酮的HF风险不受基线HF风险水平影响。

研究设计与样本

  • IRIS试验二次分析,纳入3851例无糖尿病但胰岛素抵抗的缺血性卒中或TIA患者,随机1:1接受吡格列酮或安慰剂,随访≤5年。
  • HF事件由外部评审裁定,采用时间-事件方法分析治疗效果,基线HF风险评分通过Cox模型逐步选择构建。

主要发现

  • 5年HF风险吡格列酮组4.1%、安慰剂组4.2%,无差异;HF住院风险2.9% vs 2.3%(P=0.36)。
  • 基线HF风险低、中、高亚组吡格列酮vs安慰剂HR分别为1.03(0.61-1.73)、1.10(0.56-2.15)、1.08(0.58-2.01),交互P=0.98。
  • 发生心梗者HF风险显著高于未发生者(吡格列酮31.4% vs 2.7%;安慰剂25.7% vs 2.4%;P<0.0001)。
  • 水肿、呼吸困难、体重增加不预测HF住院,但导致更多剂量下调,吡格列酮平均剂量低于安慰剂(29±17 mg vs 33±15 mg,P<0.0001)。
  • 吡格列酮降低卒中、心梗或HF住院复合终点(HR 0.78,P=0.007)。

关键数值与推荐

  • HF风险因素包括高龄、房颤、高血压、肥胖、水肿、高C反应蛋白和吸烟。
  • 复合终点为卒中、心肌梗死和HF住院。

临床怎么用

  • 对胰岛素抵抗的缺血性卒中或TIA患者,在监测和剂量调整下使用吡格列酮可不增加HF风险并获得净心血管获益。
  • 基线HF风险评分不宜作为排除吡格列酮的依据。
  • 用药期间出现水肿、呼吸困难或体重增加时应调整剂量而非直接停药。

局限性

  • 为IRIS试验二次分析,HF事件数量较少。
  • 随访时间≤5年,长期HF风险未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The IRIS trial (Insulin Resistance Intervention After Stroke) demonstrated that pioglitazone reduced the risk for both cardiovascular events and diabetes mellitus in insulin-resistant patients. However, concern remains that pioglitazone may increase the risk for heart failure (HF) in susceptible individuals. METHODS: In IRIS, patients with insulin resistance but without diabetes mellitus were randomized to pioglitazone or placebo (1:1) within 180 days of an ischemic stroke or transient ischemic attack and followed for ≤5 years. To identify patients at higher HF risk with pioglitazone, we performed a secondary analysis of IRIS participants without HF history at entry. HF episodes were adjudicated by an external review, and treatment effects were analyzed using time-to-event methods. A baseline HF risk score was constructed from a Cox model estimated using stepwise selection. Baseline patient features (individually and summarized in risk score) and postrandomization events were examined as possible modifiers of the effect of pioglitazone. Net cardiovascular benefit was estimated for the composite of stroke, myocardial infarction, and hospitalized HF. RESULTS: Among 3851 patients, the mean age was 63 years, and 65% were male. The 5-year HF risk did not differ by treatment (4.1% pioglitazone, 4.2% placebo). Risk for hospitalized HF was low and not significantly greater in pioglitazone compared with placebo groups (2.9% versus 2.3%, P=0.36). Older age, atrial fibrillation, hypertension, obesity, edema, high C-reactive protein, and smoking were risk factors for HF. However, the effect of pioglitazone did not differ across levels of baseline HF risk (hazard ratio [95% CI] for pioglitazone versus placebo for patients at low, moderate, and high risk: 1.03 [0.61-1.73], 1.10 [0.56-2.15], and 1.08 [0.58-2.01]; interaction P value=0.98). HF risk was increased in patients with versus those without incident myocardial infarction in both groups (pioglitazone: 31.4% versus 2.7%; placebo: 25.7% versus 2.4%; P<0.0001). Edema, dyspnea, and weight gain in the trial did not predict HF hospitalization but led to more study drug dose reduction with a lower mean dose of pioglitazone versus placebo (29±17 mg versus 33±15 mg, P<0.0001). Pioglitazone reduced the composite outcome of stroke, myocardial infarction, or hospitalized HF (hazard ratio, 0.78; P=0.007). CONCLUSIONS: In IRIS, with surveillance and dose adjustments, pioglitazone did not increase the risk of HF and conferred net cardiovascular benefit in patients with insulin resistance and cerebrovascular disease. The risk of HF with pioglitazone was not modified by baseline HF risk. The IRIS experience may be instructive for maximizing the net benefit of this therapy. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00091949.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Young LH, Viscoli CM, Schwartz GG, et al. Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. Circulation. 2018. PMID: 29934374. doi:10.1161/CIRCULATIONAHA.118.034763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。